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Key points
From summary and commentary
Opinions vary about how much favourable
evidence should accumulate before drug
consumption rooms are implemented in
countries yet to have tried this strategy.
Although the published literature is large
and almost unanimous in its support for
drug consumption rooms, its
methodological limitations prevent positive
outcomes being directly attributed to drug
consumption rooms, and, in a point that
tends to be overlooked, do not help
societies decide how to optimise the design
of facilities to maximise any life-saving
benefits.
Review analysis
This entry is our analysis of a review or synthesis of research findings considered
particularly relevant to improving outcomes from drug or alcohol interventions in the UK.
The original review was not published by Findings; click Title to order a copy. Free reprints
may be available from the authors – click prepared e-mail. The summary conveys the
findings and views expressed in the review. Below is a commentary from Drug and Alcohol
Findings.
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How high should the evidence bar be set when deciding whether to endorse drug consumption
rooms?
SUMMARY Drug consumption rooms (also known as supervised consumption sites) provide
hygienic and supervised spaces for people to inject or otherwise consume illicit drugs. They
operate in more than 10 countries, and have mostly emerged as ‘bottom-up’ responses to the
harms experienced by people who inject drugs, including HIV and overdose deaths.
Efforts to summarise the evidence base (1 2 3 4 5)
have tended to reach strongly positive conclusions
about drug consumption rooms. However, there is
limited evidence demonstrating a ‘cause and effect’
relationship between drug consumption rooms and
observed positive outcomes.
On the question of whether there is enough
evidence to justify wider roll-out of drug
consumption rooms, it is common to hear the
following opposing views:
“Yes, there is sufficient evidence”: One view
notes that people are dying on the streets but
not one person has died from an overdose in a
drug consumption room. Therefore, immediate
expansion is imperative and anything less
would be immoral.
“No, there is insufficient evidence”: Another
view insists that since none of the evaluations
employ ‘gold standard’ methods of demonstrating cause and effect, we cannot be
confident in drug consumption rooms producing meaningful, positive effects.
There is, however, abundant room between those extremes, and exploring this space could help
shift the response to the question from a fight over “yes” versus “no” to, “It depends on the type
of decision and perspective”.
Aiming to provide a more nuanced assessment of the evidence base, the featured US review
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Most commonly studied drug
consumption rooms
The overwhelming majority of
studies focus on just two facilities:
• Insite in Vancouver (Canada);
• the Medically Supervised Injection
Centre (MSIC) in Sydney
(Australia).
concentrated on the findings of higher-quality research and assessed how much evidence
policymakers would need to endorse drug consumption rooms.
Of the 65 articles identified, just nine (from four drug consumption rooms in three cities)
compared changes in outcomes in neighbourhoods where a drug consumption room had
opened to control areas where they had not – a robust research design particularly
desirable in the absence of . Also reviewed were eight
simulation studies that attempted to estimate the costs and benefits of existing drug
consumption rooms at reducing disease transmission and overdose.
Main findings
Outcomes
The literature has reported favourable or no
effects on most outcomes including overdoses.
For example, one study found a significantly
greater reduction in the number of fatal
overdoses within 500 metres of Vancouver’s
Insite facility than outside that radius.
There has been no evidence that drug
consumption rooms increase crime. Multiple
studies (1 2 3) of the Sydney consumption room found no effect on crime and one study in
Vancouver suggested that crime may have fallen after the drug consumption room
opened.
Other than mixed results concerning publicly-disposed injecting equipment around a drug
consumption room in Barcelona (1 2), no studies have reported adverse outcomes
including possible unintended consequences such as prolonging drug-using careers,
reducing local property values, or normalising drug use in the eyes of young people.
The importance of scale
Nobody has died from an overdose inside a drug consumption room, which serves as a
strong argument for them having a positive effect. However, since drug consumption
rooms only supervise a small proportion of all drug use, spillover effects on behaviour
outside drug consumption rooms also matter. For context, Insite was estimated to
supervise 5% of injections in its Vancouver Downtown Eastside locality in the early 2000s,
leaving most drug use occurring outside the drug consumption room.
While drug consumption rooms do not have to supervise all injections in order to be
effective or justifiable, it is helpful to consider what it would take to supervise all
injections. Using the United States as an example, there were approximately 1.5 million
people who regularly (ie, on a daily/near daily basis) used heroin circa 2016. If these
people consumed heroin twice a day, that would come to about 1.1 billion episodes per
year. Even if all drug consumption rooms worldwide (totalling around 100) moved to the
US and expanded to be as large as Vancouver’s Insite, that would still cover less than 2%
of injecting episodes. Supervising all of them would require approximately 7,000 Insite-
like facilities and probably cost over 10 billion US dollars per year to operate – more if use
of shorter-duration opioids like fentanyl result in more injecting sessions per day (1 2) or if
drug consumption rooms committed to supervising the use of opioid pills, cocaine, or
methamphetamine. To put this into perspective, there are only about 1,500 opioid
treatment providers in the US.
Costs and benefits
Costs for supervising drug use (the most distinctive function of drug consumption rooms)
have been estimated at roughly the same in Vancouver and Sydney – the equivalent in
Canadian currency of C$7.50–C$10 per injection. This would bring the cost of supervising
all injections for someone who injects twice a day to about C$5,500–C$7,300 per year,
which is in the same ballpark as the cost of providing methadone for a year to a patient in
the United States.
randomised controlled trials
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Focusing almost exclusively on Vancouver, simulation studies have found that the
value of averting a fatal overdose or HIV infection is so high that drug consumption
rooms can pass the cost–benefit test even if the number of people affected is small
(1 2). However, many other interventions also pass that test, including medication-
assisted treatment, needle and syringe exchanges and naloxone, raising the
question of how best to distribute scarce financial resources across such
interventions.
It is unclear whether greater benefit would be achieved by investing the same
amount of resources in interventions other than drug consumption rooms due to a
lack of evidence about the magnitude of population-level benefits – firstly, because
the literature can blur the lines between the impact of a drug consumption room’s
entire suite of interventions and its supervision of consumption, and secondly,
because supervised consumption can have spillover effects on behaviour outside
drug consumption rooms as well as within the four walls.
Adequacy of literature
There is no clear-cut answer to the question of how much favourable evidence must
accumulate before implementing new drug consumption rooms – the threshold may
differ depending on who is making the decision:
• The politician is someone, such as a mayor, who faces a ‘yes’ or ‘no’ choice
about allowing drug consumption rooms, and will be held responsible for their
outcomes but not their funding or operation. The politician may care as much about
the logical consistency of drug consumption rooms as having a rigorous evidence
base. Furthermore, politicians may have a bias toward acting in response to a crisis,
but they can be sensitive to adverse side-effects, which are amplified in today’s
partisan political–media discourse.
• The planner needs to understand not just whether an intervention is effective,
but also how effective it is. Would implementation solve the underlying problem,
make a major contribution, or be just an appreciated but minor supplement to some
other primary response? And, how readily can model programmes be replicated and
brought to scale?
• The pioneer isn’t content with identifying the best existing intervention, but asks
“How can I invent something better by teasing out the strengths and weaknesses of
the existing options?” Like the planner, the pioneer cares about the magnitude of
effects, but requires that information at the level of constituent interventions (eg,
the supervised consumption element with drug consumption rooms that provide
other services), and wants to know why, not just whether, something works.
The threshold may also differ depending on the intellectual perspective:
• The academic typically insists on having very strong evidence before concluding
that a causal effect exists, but devotes less attention to interpreting the magnitude
of an effect, and is less concerned about costs or cost-effectiveness.
• The advocate might bristle at perpetual calls for more (and more rigorous)
research in the midst of a crisis, noting that no reasonable person would wait for a
randomised control trial evaluating parachutes before donning one when leaping
from a plane. From their perspective, the intervention ‘makes sense’ and there are
more than enough reviews of the broader literature that provide nearly unanimous
support for drug consumption rooms. There is also a sizeable literature representing
the perspective of drug consumption room clients, not distant social planners, which
investigate important but hard-to-measure outcomes, such as how drug
consumption rooms reduce stigma or enhance access to social services in hard-to-
reach populations, rather than whether drug consumption rooms are cost-effective
ways to spend taxpayers’ dollars.
• The allocator of scarce resources wants to know whether drug consumption
rooms save more lives per dollar than other available alternatives, such as
expanding access to naloxone and opioid substitute medications.
The authors’ conclusions
There is minimal evidence demonstrating a ‘cause and effect’ relationship between
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drug consumption rooms and favourable outcomes. However, the published
literature is large and almost unanimous in its support for drug consumption
rooms, and there is little to no basis for concern about drug consumption
rooms producing adverse effects.
How high the evidence bar should be set when stakeholders are deciding
whether to endorse drug consumption rooms depends upon the type of
decision-maker and their perspective. The distinctions the featured paper
drew between politicians, planners and pioneers, and between academics,
advocates and allocators of scarce resources, could help different interested
parties to walk these fine lines in harmony. It could also open up space to
discuss how research does not currently (but could in the future) allow society
to optimise the design of drug consumption rooms in order to maximise
potential life-saving benefits.
COMMENTARY Drug consumption rooms tend to emerge from
local initiatives aimed at reducing the harms of public drug consumption, and
are not designed or implemented in ways that permit evaluation by the
scientific ‘gold standard’ of a randomised controlled trial – randomly allocating
people to demonstrate the causal effect of drug consumption rooms, or more
specifically the supervised consumption element of drug consumption rooms.
Having said that, there are examples of robust research designs in the
evidence base, including nine studies identified in the featured paper which
compared changes in outcomes in neighbourhoods where a drug consumption
room had opened versus control areas where they had not.
In 2006, the UK Independent Working Group on Drug Consumption Rooms
concluded that “the methodological problems involved … should not detract
from [drug consumption rooms’] considerable success”. On balance, the
evidence suggests that drug consumption rooms can have a positive impact
on the health of their clients, for example through ensuring (relatively) safe
and hygienic injecting in the facility, providing personalised advice and
information on safe injecting practices, recognising and responding to
emergencies, and providing access to a range of other on-site and off-site
interventions and support. And, even without a randomised trial, it may be
possible to at least estimate the likelihood that an intervention (in this case, a
drug consumption room) is having a positive or negative impact. For instance,
it may not be possible to determine impacts on the transmission of infectious
diseases, but it is possible to observe impacts on self-reported needle and
syringe sharing – the main cause of transmission among people who use
drugs.
The featured paper made a unique contribution to the debate about drug
consumption rooms, diverging from the well-trodden narrative that the
evidence base provides almost unanimous support for safer injecting facilities,
to look at gaps in the evidence base and the adequacy of the research
depending on who is reading it. The distinctions made between different
stakeholder groups may be useful in helping to establish a more nuanced
attitude to drug consumption rooms by looking at the interests of those most
likely to be involved in discussions and decisions around them being
established. This could serve to facilitate the provision of drug consumption
rooms by anticipating the variety of views and possible opposition. However,
the authors may have been over-optimistic if their goal for the paper was to
facilitate “harmony” between stakeholders with divergent perspectives.
“We hope that the distinctions we have drawn, between decision-
makers who are politicians, planners and pioneers, and between
the perspectives of academics, advocates and allocators of scarce
resources, help different interested parties to walk these fine lines
in harmony.”
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The analysis and commentary elucidated the reasons for different
appraisals of the evidence base according to decision-making and
intellectual responsibilities, but did not address the ideological struggle
between acceptance and zero-tolerance of illegal drug use at the root
of the debate, the power dynamics between stakeholders (eg, the way
that politicians may act as or be perceived as gatekeepers or
roadblocks to lifesaving interventions), or the overlap between
stakeholder groups (eg, people whose academic area of study is
motivated by social justice).
There are currently no drug consumption rooms in the UK, despite
concerns over the harm caused by public injecting, and concerns that
the needs of the target group of drug consumption rooms are
continuing not to be met by existing services alone. According to recent
statements from the Home Office and Prime Minister, the UK
Government has “no intention” (1 2) and “no plans” to introduce drug
consumption rooms.
Other interventions identified in the paper may serve some of the
functions of drug consumption rooms, however, may not all be equally
accessible to the target group of drug consumption rooms. For
example, some would seem to be appointment-based rather than, as
with drug consumption rooms, attended on a drop-in basis. Therefore,
when the authors posed the (understandable) question about whether
greater benefit would be achieved by investing the same amount of
resources in interventions other than drug consumption rooms, they
excluded the more fundamental argument about why drug consumption
rooms should be considered in addition to existing interventions.
Thanks for their comments on this entry in draft to Blaine Stothard, Co-Editor of Drugs
and Alcohol Today. Commentators bear no responsibility for the text including the
interpretations and any remaining errors.
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